JP2013534908A5 - - Google Patents

Download PDF

Info

Publication number
JP2013534908A5
JP2013534908A5 JP2013511636A JP2013511636A JP2013534908A5 JP 2013534908 A5 JP2013534908 A5 JP 2013534908A5 JP 2013511636 A JP2013511636 A JP 2013511636A JP 2013511636 A JP2013511636 A JP 2013511636A JP 2013534908 A5 JP2013534908 A5 JP 2013534908A5
Authority
JP
Japan
Prior art keywords
polynucleotide
mir
nucleic acid
composition
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013511636A
Other languages
English (en)
Japanese (ja)
Other versions
JP5894581B2 (ja
JP2013534908A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/058379 external-priority patent/WO2011144761A1/en
Publication of JP2013534908A publication Critical patent/JP2013534908A/ja
Publication of JP2013534908A5 publication Critical patent/JP2013534908A5/ja
Application granted granted Critical
Publication of JP5894581B2 publication Critical patent/JP5894581B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013511636A 2010-05-21 2011-05-23 骨障害及び/又は心血管障害の治療又は診断に使用する組成物 Expired - Fee Related JP5894581B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10163604 2010-05-21
EP10163604.1 2010-05-21
PCT/EP2011/058379 WO2011144761A1 (en) 2010-05-21 2011-05-23 Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders

Publications (3)

Publication Number Publication Date
JP2013534908A JP2013534908A (ja) 2013-09-09
JP2013534908A5 true JP2013534908A5 (enExample) 2014-07-10
JP5894581B2 JP5894581B2 (ja) 2016-03-30

Family

ID=44537805

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013511636A Expired - Fee Related JP5894581B2 (ja) 2010-05-21 2011-05-23 骨障害及び/又は心血管障害の治療又は診断に使用する組成物

Country Status (7)

Country Link
US (3) US20130108687A1 (enExample)
EP (1) EP2571988B1 (enExample)
JP (1) JP5894581B2 (enExample)
CN (1) CN103210085B (enExample)
BR (1) BR112012029656A2 (enExample)
CA (1) CA2800018C (enExample)
WO (1) WO2011144761A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316342A (zh) * 2013-02-28 2013-09-25 中国人民解放军沈阳军区总医院 MiR-31抑制剂用于抑制血管损伤后再狭窄的用途
GB201309882D0 (en) * 2013-06-03 2013-07-17 Isis Innovation Prevention and treatment of atrial fibrillation
WO2014197747A1 (en) * 2013-06-05 2014-12-11 The Trustees Of Columbia University In The City Of New York Exosomes for orofacial diagnostics and therapeutics
CN103627705B (zh) * 2013-10-28 2016-02-24 南京医科大学 与膀胱癌相关的piRNA生物标志物及其应用
WO2015189345A2 (en) * 2014-06-13 2015-12-17 Universität Für Bodenkultur Wien Compositions and methods for the diagnosis and treatment of bone fractures and disorders
WO2016094406A1 (en) * 2014-12-08 2016-06-16 Thomas Jefferson University Treatment and prevention of thrombosis using an anti-mir
JP6694240B2 (ja) * 2015-01-30 2020-05-13 ロート製薬株式会社 細胞の品質を評価する方法、及び細胞の品質判定キット
CN107176976B (zh) * 2016-03-11 2020-02-14 上海交通大学医学院 微小rna31前体编码多肽在制备免疫调节药物中的应用
CN107151695B (zh) * 2016-12-08 2021-11-09 青岛大学 用于检测急性心肌缺血疾病的piRNA组合及其检测方法和应用
CN110129429A (zh) * 2019-05-22 2019-08-16 昌乐县人民医院 核酸分子在制备诊断骨科疾病的产品中的应用
CN110184270A (zh) * 2019-05-31 2019-08-30 固安博健生物技术有限公司 非编码rna作为男性骨质疏松症的诊断标志物
CN110055256A (zh) * 2019-05-31 2019-07-26 固安博健生物技术有限公司 Loc105376287作为诊断男性骨质疏松症的分子标志物的用途
CN110951869B (zh) * 2020-01-02 2021-06-18 北京市创伤骨科研究所 骨质疏松诊治用生物标志物
CN111118139B (zh) * 2020-01-13 2021-06-18 北京市创伤骨科研究所 一种骨质疏松的分子靶标及其应用
CN111599476B (zh) * 2020-05-15 2023-08-11 中南大学湘雅医院 一种高血压的预测模型及其建立方法以及用于预测高血压的生物标记物
CN112746101B (zh) * 2020-12-25 2023-02-28 深圳市人民医院 一种骨质疏松诊断标志物及促进骨质疏松骨再生的核酸药物
CN114426950B (zh) * 2022-01-25 2023-08-04 北京大学口腔医学院 一种高成骨成血管的血清外泌体及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
EP0943684A3 (en) * 1998-03-10 2002-01-23 Smithkline Beecham Plc Frizzled-like polypeptides and polynucleotides
US7655785B1 (en) * 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
PT1913952E (pt) * 2002-12-05 2011-04-14 Univ Arkansas Determinantes moleculares da doença óssea do mieloma e respectivas utilizações
US7135493B2 (en) 2003-01-13 2006-11-14 Astellas Pharma Inc. HDAC inhibitor
AR043507A1 (es) 2003-03-14 2005-08-03 Lundbeck & Co As H Derivados de anilina sustituidos y composiciones farmaceuticas
EP1648914A4 (en) * 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
CA2556435C (en) * 2004-02-13 2014-08-12 The Rockefeller University Anti-microrna oligonucleotide molecules
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
KR101407707B1 (ko) 2006-04-03 2014-06-19 산타리스 팔마 에이/에스 Anti-mirna 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
WO2008013963A2 (en) 2006-07-28 2008-01-31 University Of Connecticut Fatty acid amide hydrolase inhibitors
US7993831B2 (en) * 2007-09-14 2011-08-09 Asuragen, Inc. Methods of normalization in microRNA detection assays
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
US20130210883A1 (en) 2010-05-21 2013-08-15 Johannes Grillari Lipase inhibitors

Similar Documents

Publication Publication Date Title
JP2013534908A5 (enExample)
Allen et al. Posttranscriptional mechanisms involving microRNA-27a and b contribute to fast-specific and glucocorticoid-mediated myostatin expression in skeletal muscle
CN106687602B (zh) 用于诊断和治疗骨折和骨病的组合物及方法
DK3134526T3 (en) LNC RNAs for therapy and diagnosis of cardiac hypertrophy
AU2014284836B2 (en) Respiratory disease-related gene specific siRNA, double-helical oligo RNA structure containing siRNA, compositon containing same for preventing or treating respiratory disease
Fiorillo et al. Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone
JP6919098B2 (ja) 筋強直性ジストロフィー1型に対するマイクロrnaの変調及びそのためのマイクロrnaのアンタゴニスト
JP2016199565A (ja) 血管新生、血管形成、若しくは血管修復を促進するか、又は腫瘍血管新生を阻害する方法
WO2009015071A1 (en) Screening of micro-rna cluster inhibitor pools
WO2009114681A2 (en) Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy
EA015570B1 (ru) Фармацевтическая композиция
JP2013523696A5 (enExample)
JP2010539990A (ja) アンチセンス転写物を標的とするagRNAおよびギャップマーを用いた遺伝子発現の調節方法
Philippen et al. Antisense MicroRNA therapeutics in cardiovascular disease: quo vadis?
Bengestrate et al. Genome-wide profiling of microRNAs in adipose mesenchymal stem cell differentiation and mouse models of obesity
TW201406774A (zh) 微rna之mir-15家族之抑制劑
JP2017528441A5 (enExample)
KR102547432B1 (ko) Tut4/7 발현 조절인자를 포함하는 암 예방 또는 치료용 약학적 조성물
Chang et al. miR-223 plays a key role in obesogen-enhanced adipogenesis in mesenchymal stem cells and in transgenerational obesity
Gherardi et al. Transcriptional and epigenetic analyses of the DMD locus reveal novel cis‑acting DNA elements that govern muscle dystrophin expression
JP6928001B2 (ja) 心臓リモデリングの治療及び診断のためのlncRNA Meg3
WO2014040742A1 (en) Treatment of heart disease through modulation of hypoxia-induced erna activity
WO2018047148A1 (en) Compounds for the inhibition of mirna
Chang et al. miR-223 Plays A Critical Role in Obesogen-Enhanced Adipogenesis in Mesenchymal Stem Cells and in Transgenerational Obesity
US20230181613A1 (en) Inhibitors of micro-rna 22